Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a corticosteroid presented as a nasal spray for intranasal use. It reduces inflammation and congestion associated with allergic rhinitis, seasonal and perennial allergic rhinitis, and nasal polyps in both adult and pediatric patients.

GNH USA supplies Nasonex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The product complies with EU pharmacopeial specifications and undergoes rigorous quality control to ensure consistency and safety.

Nasonex (mometasone furoate) is a nasal corticosteroid used to manage inflammatory conditions of the nasal passages.

Allergic rhinitis: reduces nasal congestion, sneezing, and itching. Seasonal allergic rhinitis: provides symptom relief during pollen seasons. Perennial allergic rhinitis: controls year‑round nasal inflammation. Nasal polyps: helps shrink polyps and improve nasal airflow.

Nasonex may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning - Headache - Nosebleeds (epistaxis) - Throat irritation

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Adrenal suppression with prolonged high‑dose use

Before initiating therapy, consider the following precautions.

Assess for active nasal infection: avoid use until infection resolves. Avoid in patients with known hypersensitivity to mometasone or formulation components. Use the lowest effective dose: limit exposure to reduce systemic effects. Monitor for signs of adrenal insufficiency during long‑term or high‑dose treatment. Caution in patients with glaucoma or cataracts: monitor intra‑ocular pressure. Store at room temperature: keep in the original container, protect from moisture and heat.

Nasonex can interact with other medications; review the following.

Major Interactions (Avoid): - Concurrent strong CYP3A4 inhibitors may increase systemic mometasone exposure. - Use with other nasal or systemic corticosteroids may amplify systemic corticosteroid effects.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole) may modestly raise mometasone levels. - Ritonavir can increase exposure; monitor for adverse effects. - Co‑administration with immunosuppressants may require clinical monitoring. - Live vaccines may have reduced efficacy; consider timing of vaccination.